Oral antiviral treatments for COVID-19 Prescribing information for GPs


Evusheld (tixagevimab and cilgavimab) has been provisionally approved by the TGA  for the prevention of COVID-19 in people who are at risk of infection but have not been exposed to the virus (pre-exposure prevention of COVID-19).

Provisional approval has been granted for pre-exposure prophylaxis of COVID-19 in people aged 12 years and older weighing at least 40 kg:

  • who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments that make it likely that they will not mount an adequate immune response to COVID-19 vaccination; or
  • for whom vaccination is not recommended due to a history of severe adverse reaction to a COVID‐19 vaccine or COVID‐19 vaccine component.

Pre-exposure prevention with Evusheld is not a substitute for vaccination in people for whom COVID-19 vaccination is recommended.

Evusheld is distributed via the National Medical Stockpile to state and territory governments. Information on access to this medicine can be found via each state/territory health department website.

See the TGA website for further information on Evusheld.

This event attracts CPD points and can be self recorded

Did you know you can now log your CPD with a click of a button?

Create Quick log